EX-99.1 2 a06-23179_1ex99d1.htm EX-99

Exhibit 99.1

Dendrite Reports Third Quarter Financial Results

Revenues of $103.0 million

GAAP E.P.S. loss of $0.14 reflects charges associated with Operational Effectiveness Program

Adjusted E.P.S of $0.09 per diluted share

Bedminster, N.J., November 2, 2006 - Dendrite International, Inc. (NASDAQ: DRTE) today reported its financial results for the quarter ended September 30, 2006.

Revenues for the quarter were $103.0 million, compared to revenues of $114.4 million in the prior year period.  Year over year revenue comparisons are negatively affected by approximately $14 million of revenue in the prior period from the Company’s largest customer primarily related to a significant one-time project.

On a GAAP basis, the Company reported a loss of $0.14 per diluted share in the third quarter 2006.  Adjusted earnings per diluted share were $0.09 in the third quarter 2006, excluding $0.21 per share in severance and asset impairment charges and $0.02 per share in compensation expense (related to stock options and shares issued under the Company’s employee stock purchase plan).  The Company reported that adjusted results also include approximately $0.02 per share of additional expense related to the implementation of its previously announced Operational Effectiveness program and strategic initiatives.  GAAP earnings were $0.24 per diluted share for the third quarter 2005.

“Dendrite’s repositioning is well underway, and our Operational Effectiveness program remains on track to generate our targeted savings of $40 million against our 2006 budget, which we expect will substantially enhance our bottom line going forward.  With our exciting product development pipeline, streamlined cost structure and strengthened management team, we believe we are well positioned to both identify and capitalize on revenue growth opportunities in the months ahead,” stated Chief Operating Officer Joe Ripp.

 

1405/1425 ROUTE 206 SOUTH • BEDMINSTER, NJ • 07921

P: 908.443.2000 • F: 908.443.2100




Segment Results

Sales solutions

Sales solutions revenue of $66.8 million was down 19% compared to $82.6 million in the third quarter of 2005, due largely to the previously noted non-recurring project in the third quarter 2005.  Operating income in this segment decreased to $7.6 million for the quarter compared to $23.0 million in the prior year period.  Third quarter 2006 Sales solutions operating income included approximately $5.8 million of restructuring charges related to severance for the Company’s Operational Effectiveness initiatives.

Marketing solutions

Marketing solutions revenue of $28.8 million in the third quarter 2006 increased 14% versus $25.3 million in the third quarter 2005.  All regions experienced growth versus the prior year.  Marketing solutions reported an operating loss of approximately $2.9 million in the third quarter 2006 compared to an operating loss of approximately $1.4 million in the third quarter of 2005.  This change was due to additional selling and marketing efforts in support of future growth in this segment, as well as third quarter 2006 restructuring costs of $1.9 million.

Emerging solutions

Emerging solutions revenue of $7.4 million increased 15% from revenue of $6.4 million in the prior year period.  The Emerging solutions segment reported operating income in the third quarter of 2006 of approximately $0.1 million; this was essentially flat compared to the same period of the prior year.  Third quarter 2006 restructuring charges were $0.1 million for this segment.

Corporate segment

Dendrite reported Corporate expenses of $13.1 million in the third quarter of 2006 compared to $4.2 million in the third quarter of 2005, primarily reflecting the substantial costs the Company is incurring as it implements its Operational Effectiveness initiative.  Costs associated with stock options and restricted stock units contributed nearly $2.0 million of additional expense in the third quarter 2006.  The third quarter 2006 Corporate segment expense also included approximately $4.9 million of restructuring charges primarily related to an asset impairment charge related to a facility that Dendrite expects to sell as part of the Company’s Operational Effectiveness initiative.  A further $2 million increase in Corporate segment expense is attributable primarily to consulting and other miscellaneous costs relating principally to the Company’s Operational Effectiveness program and other strategic initiatives.

2




 

Summary of Key Balance Sheet Items

·                  The Company generated $13.3 million of cash from operations in the third quarter 2006.

·                  Days sales outstanding (DSO) was 59 days, remaining below the Company’s target of 60-63 days

·                  The Company ended the third quarter 2006 with $84.1 million in cash and cash equivalents.

·                  Total capital expenditures were $2.9 million in the third quarter 2006.

Business Highlights

Solid business performance was seen elsewhere in all three segments.

Sales Solutions segment:

·                  Signed a global agreement with Procter and Gamble in Q406 to:

o                 Upgrade its core sales force automation solution to Dendrite’s Mobile Intelligence

o                 Extend its existing support services and prescriber data management solutions

o                 Add regional tool to enable greater territory and compliance management

·                  Secured contract expansions with Daiichi Sankyo and UCB, together adding more than 450 new sales force effectiveness users

·                  Launched the new Dendrite MICRO™ mobile phone based sales force effectiveness solution and signed the first new customer

·                  In Europe, the Company entered into a significant three-year sales rep support services agreement with a prominent pharmaceutical company to implement and manage support services for over 1000 sales representatives in France

·                  Added more than 1000 new sales force effectiveness users in Europe, including two new customers on its human centered design based Mobile Intelligence™ platform

·                  In Latin America, the Company implemented and rolled out its sales force effectiveness solution for approximately 350 users of Valeant, Mexico

·                  In Australia, the Company signed an agreement with BMS to upgrade to the latest version of Dendrite’s sales force automation solution, including a service renewal for three years.

·                  In Asia, the Company signed an agreement for its jforceNET™ sales force effectiveness solution with its first domestic Korean pharmaceutical customer, LG Life Sciences

Marketing Solutions segment:

·                  In the US, the Company closed forty new agreements with several customers, including seven with a leading pharmaceutical company for persistence campaigns and campaign management programs with a total contract value of over $ 4.5M.

·                  Acquired OPUS Health™, a leading provider of direct-to-patient persistence technologies. The acquisition enables Dendrite to add its breadth of marketing services around OPUS Health technology to deliver complete patient persistence programs and analysis.

·                  In Europe, increased penetration of our DocScan®, Physician ConnectSM and Market Research solutions, growing 32% versus the third quarter 2005.  In Japan, the Company delivered its first two Physician Connect and DocScan projects for the region, following the recent launch of those offerings in the second quarter 2006.

3




 

Emerging Solutions Segment:

·                  The Company’s Buzzeo Compliance group achieved a profitable quarter with a revenue increase of 18% year-to-date. Since its acquisition, the Company has rapidly expanded its customer base to include not only pharmaceutical companies, but also pharmaceutical distributors and pharmacy chains.

Other Matters

The Company revised its 2006 revenue outlook to approximately $419 to $424 million, down from $427 to $437 million, primarily as a result of slower than planned US Marketing Solutions sales in the second half of the year.

From time to time the Company has received expressions of interest in strategic opportunities.  As a consequence, the Board of Directors has appointed JPMorgan to advise the Board on their full range of options.  The Company stated that there could be no assurances of any action as a result of their review and that it does not intend to discuss or provide interim updates.

To participate in Dendrite’s earnings call to be telecast on November 2, 2006 at 5 p.m. EST, or to obtain replay information, please visit the Investors’ Highlights Section of our website at www.dendrite.com.

About Dendrite

Founded in 1986, Dendrite International (NASDAQ: DRTE) enables sales, marketing, clinical and compliance solutions for the global pharmaceutical industry.  The Company’s clients are located in more than 50 countries and include the world’s top 20 pharmaceutical companies. For more information, please visit www.dendrite.com.

Investor Relations
Christine Croft
908-443-4265
christine.croft@dendrite.com

Note: Dendrite is a registered trademark of Dendrite International, Inc.

FORWARD LOOKING INFORMATION:  This document contains forward-looking statements that may be identified by such forward-looking terminology as “expect,” “believe,” “anticipate,” “will,” “intend,” “plan,” “target,” “outlook,” “guidance,” and similar statements or variations. Such   forward-looking statements are based on our current expectations, estimates, assumptions and projections and involve

4




 

significant risks and uncertainties, including risks which may result from our dependence on the pharmaceutical industry; our fixed expenses in relation to fluctuating revenues and variations in customers’ budget cycles; dependence on certain major customers, including the risk associated with our largest customer’s plans to transition a significant portion of its U.S. sales force effectiveness services needs; fluctuations in quarterly revenues due to lengthy sales and implementation cycles; our ability to successfully implement our Operational Effectiveness program and to achieve the cost savings in the amounts and time periods expected or budgeted; changes in demand for our products and services attributable to any weakness  experienced in the  economy or mergers, acquisitions and consolidations in the pharmaceutical industry; risks associated with foreign currency fluctuations as they affect our non-U.S. operations; risks associated with our expanded international operations and our ability to adopt and respond successfully to the unique risks involved in our non-U.S. operations; any difference between estimated and actual stock option expense; and risks associated with reviewing strategic options and with any transaction occurring or being consummated at any subsequent time.  Other important factors that should be reviewed and carefully considered are included in the Company’s 10-K under “Factors That May Affect Future Results” and its 10-Qs and other reports filed with the SEC. Actual results may differ materially. The Company assumes no obligation for updating any such forward-looking statements to reflect actual results, changes in expectations or assumptions or other changes affecting such forward-looking statements, even if such results or changes make it clear that any such projected results will not be achieved. Any outlook and other forward-looking information is as of the date of this release only.  At any such time in the future as the Company may provide revenue, earnings and other outlook information, prior related outlook should no longer be considered current. Our outlook and other forward-looking information do not take into account or reflect any possible future acquisitions, dispositions or similar transactions which may occur.

 

5




TABLE 1

DENDRITE INTERNATIONAL, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS - GAAP

(IN THOUSANDS, EXCEPT PER SHARE DATA)

(UNAUDITED)

 

 

Three Months Ended September 30,

 

 

 

2006

 

%

 

2005

 

%

 

Change

 

 

 

 

 

 

 

 

 

 

 

 

 

Revenues:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Services & Technology:

 

 

 

 

 

 

 

 

 

 

 

Sales solutions

 

$

66,762

 

64.8

%

$

82,642

 

72.3

%

(19

)%

Marketing solutions

 

28,835

 

28.0

%

25,310

 

22.1

%

14

%

Emerging solutions

 

7,376

 

7.2

%

6,408

 

5.6

%

15

%

Total revenues

 

102,973

 

100.0

%

114,360

 

100.0

%

(10

)%

 

 

 

 

 

 

 

 

 

 

 

 

Operating Costs & Expenses:

 

 

 

 

 

 

 

 

 

 

 

Operating costs (including shipping)

 

56,172

 

54.6

%

61,252

 

53.6

%

(8

)%

Selling, general and administrative

 

39,816

(1)

38.7

%

33,395

(2)

29.2

%

19

%

Research and development

 

1,607

 

1.6

%

1,343

 

1.2

%

20

%

Restructuring and other charges

 

12,660

(3)

12.3

%

 

0.0

%

NM

 

Amortization of acquired intangible assets

 

1,074

 

1.0

%

960

 

0.8

%

12

%

Total operating costs & expenses

 

111,329

 

108.1

%

96,950

 

84.8

%

15

%

 

 

 

 

 

 

 

 

 

 

 

 

Operating (loss) income

 

(8,356

)

(8.1

)%

17,410

 

15.2

%

NM

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest income, net

 

(644

)

(0.6

)%

(150

)

(0.1

)%

NM

 

Other expense, net

 

31

 

0.0

%

35

 

0.0

%

NM

 

 

 

 

 

 

 

 

 

 

 

 

 

(Loss) income before income tax (benefit) expense

 

(7,743

)

(7.5

)%

17,525

 

15.3

%

144

%

 

 

 

 

 

 

 

 

 

 

 

 

Income tax (benefit) expense

 

(1,698

)

(1.6

)%

6,747

 

5.9

%

125

%

 

 

 

 

 

 

 

 

 

 

 

 

Net (loss) income

 

$

(6,045

)

(5.9

)%

$

10,778

 

9.4

%

156

%

 

 

 

 

 

 

 

 

 

 

 

 

Net (loss) income per share:

 

 

 

 

 

 

 

 

 

 

 

Basic

 

$

(0.14

)

 

 

$

0.25

 

 

 

NM

 

Diluted

 

$

(0.14

)

 

 

$

0.24

 

 

 

NM

 

 

 

 

 

 

 

 

 

 

 

 

 

Shares used in computing net (loss) income per share:

 

 

 

 

 

 

 

 

 

 

 

Basic

 

43,713

 

 

 

42,944

 

 

 

 

 

Diluted

 

43,713

 

 

 

44,331

 

 

 

 

 

 


(1)                               Includes $937 out of $975 total stock-based compensation expense from the adoption of SFAS 123(R) and $887 out of $905 total restricted stock expense, respectively.

(2)                               Includes $69 of restricted stock expense.

(3)                               $8,206 of severance expense and $4,454 of an asset impairment charge.

 

 

NM - Not meaningful.




TABLE 2

DENDRITE INTERNATIONAL, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS - GAAP

(IN THOUSANDS, EXCEPT PER SHARE DATA)

(UNAUDITED)

 

 

Nine Months Ended September 30,

 

 

 

2006

 

%

 

2005

 

%

 

Change

 

 

 

 

 

 

 

 

 

 

 

 

 

Revenues:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Services & Technology:

 

 

 

 

 

 

 

 

 

 

 

Sales solutions

 

$

202,316

 

64.7

%

$

230,641

 

70.1

%

(12

)%

Marketing solutions

 

90,414

 

28.9

%

79,091

 

24.0

%

14

%

Emerging solutions

 

19,753

 

6.3

%

19,141

 

5.8

%

3

%

Total revenues

 

312,483

 

100.0

%

328,873

 

100.0

%

(5

)%

 

 

 

 

 

 

 

 

 

 

 

 

Operating Costs & Expenses:

 

 

 

 

 

 

 

 

 

 

 

Operating costs (including shipping)

 

175,321

 

56.1

%

173,732

 

52.8

%

1

%

Selling, general and administrative

 

121,707

(1)

38.9

%

103,258

(2)

31.4

%

18

%

Research and development

 

4,835

 

1.5

%

4,615

 

1.4

%

5

%

Restructuring and other charges

 

15,238

(3)

4.9

%

9,372

(4)

2.8

%

63

%

Amortization of acquired intangible assets

 

3,131

 

1.0

%

3,340

 

1.0

%

(6

)%

Total operating costs & expenses

 

320,232

 

102.5

%

294,317

 

89.5

%

9

%

 

 

 

 

 

 

 

 

 

 

 

 

Operating (loss) income

 

(7,749

)

(2.5

)%

34,556

 

10.5

%

(122

)%

 

 

 

 

 

 

 

 

 

 

 

 

Interest income, net

 

(1,602

)

(0.5

)%

(315

)

(0.1

)%

NM

 

Other expense, net

 

77

 

0.0

%

32

 

0.0

%

NM

 

 

 

 

 

 

 

 

 

 

 

 

 

(Loss) income before income tax expense

 

(6,224

)

(2.0

)%

34,839

 

10.6

%

118

%

 

 

 

 

 

 

 

 

 

 

 

 

(Loss) income before income tax (benefit) expense

 

(174

)

(0.1

)%

13,413

 

4.1

%

101

%

 

 

 

 

 

 

 

 

 

 

 

 

Net (loss) income

 

$

(6,050

)

(1.9

)%

$

21,426

 

6.5

%

128

%

 

 

 

 

 

 

 

 

 

 

 

 

Net (loss) income per share:

 

 

 

 

 

 

 

 

 

 

 

Basic

 

$

(0.14

)

 

 

$

0.50

 

 

 

NM

 

Diluted

 

$

(0.14

)

 

 

$

0.49

 

 

 

NM

 

 

 

 

 

 

 

 

 

 

 

 

 

Shares used in computing net (loss) income per share:

 

 

 

 

 

 

 

 

 

 

 

Basic

 

43,638

 

 

 

42,670

 

 

 

 

 

Diluted

 

43,638

 

 

 

43,903

 

 

 

 

 

 


(1)                               Includes $3,392 out of $3,591 total stock-based compensation expense from the adoption of SFAS 123(R) and $2,213 out of $2,244 total restricted stock expense, respectively.

(2)                               Includes $103 of restricted stock expense.

(3)                               $10,248 of severance expense, $4,454 of an asset impairment charge and $536 of other expense.

(4)                               $7,649 of facility related charges and $1,723 of severance expense.

 

NM-Not Meaningful




TABLE 3

DENDRITE INTERNATIONAL, INC.

SUPPLEMENTAL FINANCIAL INFORMATION (SEE NOTES)

(IN THOUSANDS, EXCEPT PER SHARE DATA)

(UNAUDITED)

 

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

 

 

2006

 

2005

 

% Change

 

2006

 

2005

 

% Change

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total revenue - GAAP

 

$

102,973

 

$

114,360

 

(10

)%

$

312,483

 

$

328,873

 

(5

)%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Impact of foreign exchange rates (1)

 

748

 

 

 

 

3,459

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total revenue - Adjusted

 

$

103,721

 

$

114,360

 

(9

)%

$

315,942

 

$

328,873

 

(4

)%

 

 

Three Months Ended
September 30,

 

 

 

Nine Months Ended
September 30,

 

 

 

2006

 

2005

 

 

 

2006

 

2005

 

Operating (loss) income - GAAP

 

$

(8,356

)

$

17,410

 

 

 

$

(7,749

)

$

34,556

 

 

 

 

 

 

 

 

 

 

 

 

 

Stock option expense (2)

 

1,023

 

 

 

 

3,750

 

 

Surplus facility charges (3)

 

 

 

 

 

 

7,649

 

Severance charges

 

8,206

(5)

 

 

 

10,248

(5)

1,723

(4)

Asset impairment

 

4,454

(7)

 

 

 

4,454

(7)

 

Other restructuring charges

 

 

 

 

 

536

(6)

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating income - Adjusted

 

$

5,327

 

$

17,410

 

 

 

$

11,239

 

$

43,928

 

 

 

Three Months Ended
September 30,

 

 

 

Nine Months Ended
September 30,

 

 

 

2006

 

2005

 

 

 

2006

 

2005

 

Net income per share:

 

 

 

 

 

 

 

 

 

 

 

Diluted - GAAP

 

$

(0.14

)

$

0.24

 

 

 

$

(0.14

)

$

0.49

 

 

 

 

 

 

 

 

 

 

 

 

 

Stock option expense (2)

 

0.02

(8)

 

 

 

0.06

(8)

 

Surplus facility charges (3)

 

 

 

 

 

 

0.10

(9)

Severance charges

 

0.15

(10)

 

 

 

0.17

(10)

0.03

(11)

Asset impairment

 

0.06

(12)

 

 

 

0.06

(12)

 

Other restructuring charges

 

 

 

 

 

0.01

(13)

 

 

 

 

 

 

 

 

 

 

 

 

 

Diluted - Adjusted

 

$

0.09

 

$

0.24

 

 

 

$

0.17

 

$

0.62

 

 


Note: 2006 EPS does not foot down due to the mathematical rounding of the individual calculations.

 

(1)                                 The impact of exchange rates are calculated by taking 2006 local currency revenue and applying the 2005 exchange rates for comparison purposes.

 

(2)                                 Prior to January 1, 2006, the Company accounted for stock-based compensation under Accounting Principles Board, Opinion No. 25, “Accounting for Stock Issued to Employees” (“APB 25”).  In accordance with APB 25, the Company historically used the intrinsic value method to account for stock-based compensation expense.  Under APB 25, stock options and shares issued under the Company’s employee stock purchase plan were not an expense for accounting purposes and, as a result, no compensation expense is included in the 2005 reporting period related to these items.  As of January 1, 2006, the Company accounts for stock-based compensation expense, including expense related to stock options and shares issued under the employee stock purchase program, under the fair value method of Statement of Financial Accounting No. 123(R), “Shared-Based Payment” (“FAS 123(R)”).  As the Company adopted the modified prospective method, results for prior periods have not been restated under the fair value method for GAAP purposes.

 

(3)                                 The surplus facility charges relates to vacating a New Jersey facility and for additional facilities vacated in previous periods due to changes in market conditions, as well as the write-off of leasehold improvements associated with the exited facility.

 

(4)                                 The 2005 severance charges relates to the elimination of certain senior and mid-level management positions.

 

(5)                                 The 2006 severance charges relates to the elimination of certain positions relating to our Operational Effectiveness initiative (“OE”).

 

(6)                                 The 2006 other restructuring charges primarily relates to the refocusing of our Japanese business.

 

(7)                                 The 2006 asset impairment charge relates to a facility held for sale that was reduced to its estimated fair market value less costs to sell.

 

(8)                                 The tax effect using the marginal tax rate is $352 and $1,248 for the three and nine months ended September 30, 2006, respectively.

 

(9)                                 The tax effect using the marginal tax rate is $3,075 for the nine months ended September 30, 2005.

 

(10)                          The tax effect using the marginal tax rate is $1,658 and $2,352 for the three and nine months ended September 30, 2006, respectively.

 

(11)                          The tax effect using the marginal tax rate is $487 for the nine months ended September 30, 2005.

 

(12)                          The tax effect using the marginal tax rate is $1,782 for the three and nine months ended September 30, 2006.

 

(13)                          The tax effect using the marginal tax rate is $226 for the nine months ended September 30, 2006.




TABLE 4

DENDRITE INTERNATIONAL, INC.

SEGMENT REVENUE, OPERATING INCOME (LOSS) AND RESTRUCTURING AND OTHER CHARGES

(IN THOUSANDS)

(UNAUDITED)

 

 

For the Three Months Ended September 30, 2006

 

 

 

Sales
Solutions

 

Marketing
Solutions

 

Emerging
Solutions

 

Corporate

 

Total

 

Revenue

 

$

66,762

 

$

28,835

 

$

7,376

 

$

 

$

102,973

 

Operating income (loss)

 

$

7,570

 

$

(2,919

)

$

137

 

$

(13,144

)

$

(8,356

)

Restructuring charges

 

$

5,758

 

$

1,930

 

$

63

 

$

4,909

 

$

12,660

 

 

 

 

For the Three Months Ended September 30, 2005

 

 

 

Sales
Solutions

 

Marketing
Solutions

 

Emerging
Solutions

 

Corporate

 

Total

 

Revenue

 

$

82,642

 

$

25,310

 

$

6,408

 

$

 

$

114,360

 

Operating income (loss)

 

$

23,019

 

$

(1,440

)

$

69

 

$

(4,238

)

$

17,410

 

Restructuring charges

 

$

 

$

 

$

 

$

 

$

 

 

 

 

For the Nine Months Ended September 30, 2006

 

 

 

Sales
Solutions

 

Marketing
Solutions

 

Emerging
Solutions

 

Corporate

 

Total

 

Revenue

 

$

202,316

 

$

90,414

 

$

19,753

 

$

 

$

312,483

 

Operating income (loss)

 

$

33,751

 

$

(8,253

)

$

(379

)

$

(32,868

)

$

(7,749

)

Restructuring charges

 

$

6,517

 

$

2,884

 

$

67

 

$

5,770

 

$

15,238

 

 

 

 

For the Nine Months Ended September 30, 2005

 

 

 

Sales
solutions

 

Marketing
solutions

 

Emerging
solutions

 

Corporate

 

Total

 

Revenue

 

$

230,641

 

$

79,091

 

$

19,141

 

$

 

$

328,873

 

Operating income (loss)

 

$

56,433

 

$

(3,566

)

$

970

 

$

(19,281

)

$

34,556

 

Restructuring charges

 

$

 

$

 

$

 

$

9,372

 

$

9,372

 

 




TABLE 5

DENDRITE INTERNATIONAL, INC.

CONSOLIDATED BALANCE SHEETS

(IN THOUSANDS, EXCEPT SHARE DATA)

(UNAUDITED)

 

 

September 30,

 

December 31,

 

 

 

2006

 

2005

 

Assets

 

 

 

 

 

 

 

 

 

 

 

Current Assets:

 

 

 

 

 

Cash and cash equivalents

 

$

84,147

 

$

66,145

 

Accounts receivable, net

 

67,106

 

80,167

 

Prepaid expenses and other current assets

 

7,945

 

8,544

 

Asset held for sale

 

8,545

 

 

Deferred income taxes

 

13,035

 

8,848

 

Total current assets

 

180,778

 

163,704

 

 

 

 

 

 

 

Property and equipment, net

 

38,578

 

52,592

 

Other assets

 

9,355

 

8,856

 

Goodwill

 

92,332

 

90,440

 

Intangible assets, net

 

27,038

 

25,083

 

Capitalized software development costs, net

 

10,380

 

10,341

 

Deferred income taxes

 

12,011

 

11,991

 

 

 

$

370,472

 

$

363,007

 

Liabilities and Stockholders’ Equity

 

 

 

 

 

 

 

 

 

 

 

Current Liabilities:

 

 

 

 

 

Accounts payable

 

$

8,138

 

$

7,677

 

Income taxes payable

 

8,272

 

9,518

 

Capital lease obligations

 

1,408

 

1,383

 

Accrued compensation and benefits

 

18,887

 

17,950

 

Accrued professional and consulting fees

 

6,164

 

5,690

 

Accrued restructuring and other charges

 

8,138

 

1,490

 

Other accrued expenses

 

20,376

 

17,468

 

Purchase accounting restructuring accrual

 

960

 

1,601

 

Deferred revenues

 

15,430

 

18,680

 

Total current liabilities

 

87,773

 

81,457

 

 

 

 

 

 

 

Capital lease obligations

 

389

 

1,648

 

Purchase accounting restructuring accrual

 

2,269

 

3,009

 

Accrued restructuring and other charges

 

3,387

 

4,143

 

Deferred rent

 

5,425

 

5,740

 

Other non-current liabilities

 

5,617

 

5,595

 

 

 

 

 

 

 

Stockholders’ Equity:

 

 

 

 

 

Preferred stock, no par value, 15,000,000 shares authorized, none issued

 

 

 

Common stock, no par value, 150,000,000 shares authorized, 46,583,869 and 46,353,252 shares issued; 43,722,566 and 43,491,949 shares outstanding at September 30, 2006 and December 31, 2005, respectively

 

153,728

 

149,947

 

Retained earnings

 

142,899

 

148,948

 

Deferred compensation

 

 

(4,419

)

Accumulated other comprehensive income (loss)

 

722

 

(1,324

)

Less treasury stock, at cost

 

(31,737

)

(31,737

)

 

 

 

 

 

 

Total stockholders’ equity

 

265,612

 

261,415

 

 

 

$

370,472

 

$

363,007

 

 




TABLE 6

DENDRITE INTERNATIONAL, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(IN THOUSANDS)

(UNAUDITED)

 

 

Nine Months Ended September 30,

 

 

 

2006

 

2005

 

Operating activities:

 

 

 

 

 

Net (loss) income

 

$

(6,050

)

$

21,426

 

Adjustments to reconcile net (loss) income to net cash provided by operating activities:

 

 

 

 

 

Depreciation and amortization

 

19,090

 

18,026

 

Asset impairment

 

4,454

 

1,030

 

Stock-based compensation

 

5,941

 

103

 

Deferred income taxes

 

(3,869

)

(2,277

)

Excess tax benefits from stock-based awards

 

(229

)

 

Changes in assets and liabilities, net of effects from acquisitions:

 

 

 

 

 

Decrease (increase) in accounts receivable

 

14,725

 

(1,825

)

Decrease in prepaid expenses and other current assets

 

860

 

56

 

Increase in other assets

 

(368

)

(1,277

)

Increase in accounts payable and accrued expenses

 

567

 

1,599

 

Increase in accrued restructuring and other charges

 

5,829

 

6,618

 

Decrease in purchase accounting restructuring accrual

 

(1,118

)

(2,180

)

Decrease in income taxes payable

 

(1,004

)

(1,621

)

(Decrease) increase in deferred revenue

 

(3,579

)

221

 

Decrease in other non-current liabilities

 

(2

)

(70

)

 

 

 

 

 

 

Net cash provided by operating activities

 

35,247

 

39,829

 

 

 

 

 

 

 

Investing activities:

 

 

 

 

 

Acquisitions, net of cash acquired

 

(5,706

)

(21,439

)

Purchases of property and equipment

 

(9,863

)

(22,633

)

Additions to capitalized software development costs

 

(3,668

)

(3,845

)

 

 

 

 

 

 

Net cash used in investing activities

 

(19,237

)

(47,917

)

 

 

 

 

 

 

Financing activities:

 

 

 

 

 

Payments on capital lease obligations

 

(1,234

)

(1,241

)

Excess tax benefits from stock-based awards

 

229

 

 

Issuance of common stock

 

2,030

 

10,938

 

 

 

 

 

 

 

Net cash provided by financing activities

 

1,025

 

9,697

 

 

 

 

 

 

 

Effect of foreign exchange rate changes on cash

 

967

 

(1,011

)

 

 

 

 

 

 

Net increase in cash and cash equivalents

 

18,002

 

598

 

Cash and cash equivalents, beginning of year

 

66,145

 

64,020

 

 

 

 

 

 

 

Cash and cash equivalents, end of period

 

$

84,147

 

$

64,618